Stay updated with breaking news from Clinical Trials Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.
One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite.
A lack of diversity has persisted for years in the U.S, limiting patients' access to potentially effective new drugs and therapies.